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Y25.2-30.2). Predictors of patient satisfaction in the PD group were absence of pain
during closure, decreased TTA, and drastic reductions in TTD; the latter contributed
indirectly to signiﬁcant cost-savings in the PD group (1,282.3 118.3 vs. 2,271.4 121.1
dollars, respectively; P<0.001) and incremental cost savings by strategy also favored
closure over MC ($89,124.5).
CONCLUSIONS ProGlide is safe and effective for femoral artery closure in patients
who ambulate within 30 min after cardiac catheterization; all of which translated into
improved patient satisfaction and substantial cost savings.COMPLEX CORONARY INTERVENTION
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BACKGROUND The clinical beneﬁts of paxlitaxel-coated balloon angioplasty (PCB)
have been extensively studied in bare metal stent in-stent restenosis (BMS-ISR) and in
drug eluting stent in-stent restenosis (DES-ISR). The GARO Registry is a dedicated ‘all
comers’ study in anunselected patient populationwithDES-ISR to elucidate the clinical
beneﬁts of PCB angioplasty for various types of DES-ISR in a routine clinical setting.
METHODS Under the supervision of the GARO (Groupe Angioplastie de la Région
Ouest) all data for patients treated by the PCB based on the Paccocath Technology
(SeQuent Please, B.Braun Melsungen AG) for In DES-ISR were collected in a pro-
spective data base. Quantitative analyses of the angiography of the procedure were
made by an independent core lab. The primary endpoint was clinically driven TLR at
9 months while secondary endpoints consisted of the clinically driven rates of MACE,
MI and cardiac death.
RESULTS A total of 206 patients (67.7  10.3 y, 80.6% male gender) with 210 DES-ISR
lesions were recruited in 15 French study centers. Major cardiovascular risk factors
were diabetes (41.3%), hypertension (69.4%), hypercholesterolemia (75.7%) and his-
tory of smoking (47.6%). STEMI (3.9%) and NSTEMI (13.1%) were present at baseline.
Lesion characteristics were 3.02  0.64 mm (reference vessel diameter) and 14.6 
6.5 mm (lesion length). Treated vessels were LAD (37.6%), RCA (28.6%), LCX (27.6%)
and others (6.2%). Cypher-ISR (36.7%) was the most common type of DES-ISR fol-
lowed by Taxus-ISR (20.0%), Xience-ISR (20.0%), Promus-ISR (8.1%), Endeavor-ISR
(5.7%) and others (9.5%). ISR patterns were focal (52.9%) and diffuse (47.1%). 9-month
follow-up was available in 90.8% (187/206) of all patients. The duration between DES
implantation and restenosis was 3.0  2.4 years.
The 9-month TLR rate was 7.0% (13/187) whereas incidences of MI and cardiac
death were 4.3% (8/187) and 2.1% (4/187) respectively. The composite MACE rate at 9
months was 10.2% (19/187).
CONCLUSIONS Up to date this is the largest prospective registry in an unselected
patient population with DES-ISR treated with PCB angioplasty. The rates for TLR and
MACE were low and seem to be an attractive alternative treatment option despite the
lack of reimbursement in France.
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BACKGROUND Treatment of calciﬁed lesions with balloon angioplasty has been
associated with a low success rate and high procedural complications. Rotational
atherectomy (RA) improved acute results, but a high restenosis rate remained a
problem. Therefore, the purpose of this study was to evaluate the clinical and
angiographic outcome of patients with complex and calciﬁed lesions treated with a
combination of RA and second-generation drug-eluting stent (DES) implantation.
METHODS Consecutive 55 patients received combination therapy of RA and second-
generation DES implantation at de novo lesion of native coronary artery with severe
calciﬁcation between June 2009 and December 2012. Zotarolimus-eluting stents
(ZES), biolimus-eluting stent (BES), and everolimus-eluting stents (EES) were used in
14, 7, and 34 patients, respectively. 39 patients (ZES, BES, and EES were used in 12, 6,
21 patients) received one-year follow-up angiography. The clinical and angiographic
outcome was compared among those 3 groups of different DES.
RESULTS Only one patient was dead (a cause was unknown). Target lesion revascu-
larization (TLR) rate was 0% among 3 groups. The late loss was larger in ZES than in
BES or EES (ZES vs. BES vs. EES: 0.370.20mm vs. 0.200.10mm vs. 0.160.15mm,
p<0.05).CONCLUSION The clinical outcome of 3 second-generation DES used in combination
with RA was very good, although the culprit lesions were complex with severe
calciﬁcation. Combination therapy of RA and second-generation DES appeared ac-
ceptable.
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INTRODUCTION Implantation of stiff permanent metallic implants alters blood
rheology especially at the inﬂow and outﬂow edge of the stents probably contributing
to early and late stent failure. Short Polymeric Bioresorbable vascular scaffolds (BVS)
have shown to have less impact on the natural curvature of the stent vessel compared
to Metal platform stents (MPS). The impact of long BVS on vessel curvature is
unknown.
OBJECTIVES The aim of this study was to determine if there are any signiﬁcant dif-
ferences in terms of curvature of the treated vessel after the deployment of either a
metallic stent or a polymeric scaffold device in long lesions.
METHODS This retrospective study compares 32 patients who received an MPS
(Xience, Abbott Vascular, Santa Clara, CA, US) with 32 patients treated with the ever-
olimus-eluting bioresorbable vascular scaffold (BVS-Absorb, Abbott Vascular, Santa
Clara, California). All patients received 1 BVS Absorb or MPS with a length of 28mm
deployed singly in long coronary lesions. The primary end point measured was the
relative region curvature (%) evaluated with dedicated software by angiography.
RESULTS There were 22 (68.8%) males in each group. There was no difference in
median age [BVS vs MPS: 59.6 yrs vs 64.9 yrs, p¼0.453)]. There was a signiﬁcant
difference in clinical presentation of ACS/STEMI (BVS vs MPS: 68.8% vs 40.6%, p¼
0.024). The left anterior descending artery was the most treated vessel in both groups
(BVS vs MPS: 46.9% vs 40.6%, p¼ 0.857). Pretreatment length was 22.19 mm vs
20.38 mm in the BVS and MPS groups respectively (p¼0.803). There was no signiﬁ-
cant differences in reference vessel diameter, minimal lumen diameter and per-
centage diameter stenosis in both groups. Pretreatment Diastolic curvature (DC) was
greater in the BVS group compared with the MPS group (0.305 cm-1 vs 0.257 cm-1, p¼
0.803). There was a signiﬁcant decrease in median DC in the MPS group post-treat-
ment than pre-treatment (from 0.257 cm-1 to 0.199 cm-1, p¼ 0.001). There was a
decrease in median DC in the BVS group post-treatment which trends towards sig-
niﬁcance (from 0.305 cm-1 to 0.283 cm-1, p¼ 0.056). Median Percentage relative
change in DC was signiﬁcantly lower in the BVS group compared with the MPS group
(BVS vs MPS: 7.48% vs 29.4%, p¼ 0.024). By univariate analysis, device use was an
independent predictor of change in curvature (p ¼ 0.022).
CONCLUSIONS In the deployment of long coronary scaffolds/ stents (28mm in
length), bioresorbable vascular scaffolds provides better conformability compared
with MPS.
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BACKGROUND Percutaneous coronary intervention (PCI) nowadays has become
standard of care in symptomatic coronary artery disease (CAD. Lesion localization,
severe calciﬁcations, and vessel tortuosity may challenge the skills of the operator
and increase the risk of procedural complications. Coronary computed tomography
angiography (CCTA) has become a promising non-invasive imaging technique, pre-
procedural lesion characterization by CCTA might contribute to predict PCI
complexity in extensive and complex CAD.
AIM To determine the predictive value of coronary plaque characterization as
detected by 64- slice multi-detector Computed tomography(MDCT) in prediction of
the procedural complexity of elective percutaneous coronary non CTO intervention.
PATIENTS Retrospective study involving 45 patients in whom PCIs were performed for
60 single coronary lesions within 6 months of pre-procedural CCTA at ICC hospital.
METHODS All patients had MDCT coronary angiography The CT derived parameters
included inour studywas: calciumscoring,plaqueanatomy (site, sidebranch involvement,
degree of stenosis, morphological type), plaque length, volume, density and area.
RESULTS Median Agatston score was signiﬁcantly higher in lesions with complex as
compared to those with non-complex interventions with a mean of 266.51 155.93vs
168.76  70.53 with the P value ¼ 0.034. Regarding plaque density, Hounsﬁeld Units
were higher in lesions with complex as compared to non-complex PCI (371.85 (48.0 to
